uroguanylin and Kidney-Failure--Chronic

uroguanylin has been researched along with Kidney-Failure--Chronic* in 2 studies

Other Studies

2 other study(ies) available for uroguanylin and Kidney-Failure--Chronic

ArticleYear
Structural impact analysis of missense SNPs present in the uroguanylin gene by long-term molecular dynamics simulations.
    Journal of theoretical biology, 2016, 12-07, Volume: 410

    The guanylate cyclase activator 2B, also known as uroguanylin, is part of the guanylin peptide family, which includes peptides such as guanylin and lymphoguanylin. The guanylin peptides could be related to sodium absorption inhibition and water secretion induction and their dysfunction may be related to various pathologies such as chronic renal failure, congestive heart failure and nephrotic syndrome. Besides, uroguanylin point mutations have been associated with essential hypertension. However, currently there are no studies on the impact of missense SNPs on uroguanylin structure. This study applied in silico SNP impact prediction tools to evaluate the impact of uroguanylin missense SNPs and to filter those considered as convergent deleterious, which were then further analyzed through long-term molecular dynamics simulations of 1μs of duration. The simulations suggested that all missense SNPs considered as convergent deleterious caused some kind of structural change to the uroguanylin peptide. Additionally, four of these SNPs were also shown to cause modifications in peptide flexibility, possibly resulting in functional changes.

    Topics: Heart Failure; Humans; Kidney Failure, Chronic; Molecular Dynamics Simulation; Mutation, Missense; Natriuretic Peptides; Nephrotic Syndrome; Polymorphism, Single Nucleotide; Structure-Activity Relationship

2016
Plasma concentration of uroguanylin in patients on maintenance dialysis therapy.
    Nephron, 2000, Volume: 84, Issue:3

    Uroguanylin, originally isolated from urine, is a new natriuretic peptide. Its plasma level is increased in association with renal impairment and fluid retention in patients with renal diseases.. Uroguanylin concentrations were measured in patients on hemodialysis (HD, n = 76) and those on continuous ambulatory peritoneal dialysis (CAPD, n = 10) using a sensitive ra- dioimmunoassay for human uroguanylin.. Plasma concentrations of immunoreactive (ir)-uroguanylin in the patients on HD and CAPD (212.0 +/- 17.4 and 245.3 +/- 39.5 fmol/ml) were significantly higher than the value for the normal controls (5.0 +/- 0.3 fmol/ml). Plasma ir-uroguanylin levels before the start of regular HD were correlated with predialysis excess weight based on their dry weights (r = 0.33, p < 0.01) and with dialysis duration (r = 0.26, p < 0.05). The plasma levels in patients with HD, for whom high-flux membranes were used, were decreased at the end of regular HD as compared with the prior levels (p < 0.05), but not in those who underwent HD with conventional membranes.. These findings suggest that the plasma ir-uroguanylin level is related to the patient's volume status as well as renal impairment. Whether the accumulation of uroguanylin has a pathological effect has yet to be determined.

    Topics: Adult; Atrial Natriuretic Factor; Body Weight; Female; Humans; Immunoassay; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Natriuretic Peptides; Peptides; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis

2000